# Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

> **NCT02025881** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 29 (actual)

## Conditions studied

- High-risk Medulloblastoma

## Interventions

- **DRUG:** Carboplatin + etoposide
- **DRUG:** Thiotepa
- **DRUG:** Cyclophosphamide + Busilvex
- **DRUG:** Temozolimide + Irinotecan
- **COMBINATION_PRODUCT:** Etoposide + radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02025881
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09-14
- **Primary completion:** 2020-10-25
- **Final completion:** 2020-10-25
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025881, "Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02025881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*